Clinical trials: Ritonavir
HIV-1
Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1
The purpose of this study is to assess whether maraviroc administered once daily is non-inferior to emtricitabine/tenofovir also administered once daily each in combination with darunavir/ritonavir in the treatment of…
- Trial name
- MODERN (NCT01345630)
- Testing
- Maraviroc, Emtricitabine/tenofovir, darunavir/ritonavir 800/100 mg
- Where
- 177 sites in United States, Australia and 17 more
- Volunteers
- 813 people
- Sponsor
- ViiV Healthcare
Non Small Cell Lung Cancer
131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer (NSCLC)
The aim of this feasibility study is to determine the therapeutic potential of the L19SIP antibody, labeled with the radionuclide 131I in combination with radiochemotherapy, for the treatment of patients with newly diagnosed…
- Trial name
- NCT01124812
- Testing
- 131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy
- Where
- 2 sites in Italy
- Volunteers
- 3 people
- Sponsor
- Philogen S.p.A.
Castration-resistant Prostate Cancer
ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer
This is a safety, feasibility and pharmacokinetic study to confirm that the recommended safe dose and schedule of ModraDoc006/r (oral docetaxel with ritonavir) as determined in a previous phase I study is also safe and feasible…
- Trial name
- NCT03136640
- Testing
- ModraDoc006/r
- Where
- 4 sites in Netherlands
- Volunteers
- 23 people
- Sponsor
- Modra Pharmaceuticals
Healthy Subjects, Infection, Human Immunodeficiency Virus
GSK1349572 Drug Interaction Study With Protease Inhibitors
A study in healthy volunteers to determine whether there is a drug interaction between GSK1349572 and the HIV protease inhibitors lopinavir/ritonavir and darunavir/ritonavir
- Trial name
- NCT00774735
- Testing
- GSK1349572
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Solid Tumor, Adult
Food Effect Study of ModraDoc006 in Combination With Ritonavir
This study aims to evaluate the effect of food on the pharmacokinetics of ModraDoc006 in combination with ritonavir, in an open-label, cross-over design.
- Trial name
- NCT03147378
- Testing
- ModraDoc006/r
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- Modra Pharmaceuticals
Chronic Hepatitis C Infection
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
The purpose of this study is to evaluate the safety and efficacy of ABT-450, ritonavir and ABT-267 (ABT-450/r/ABT-267; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) co-administered with ribavirin (RBV)…
- Trial name
- NCT01715415
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin
- Volunteers
- 395 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Healthy
Study in Healthy Adults to Evaluate the Bioavailability of Two Test Tablet Formulations of ABT-450
The objective of this study is to assess the relative bioavailability of two test tablet formulations of ABT-450 as compared to the ABT-450 hard gelatin capsule formulation as a reference.
- Trial name
- NCT01091649
- Testing
- ABT-450, ritonavir
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Abbott
HIV
Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients
The purpose of this study is to describe the safety, efficacy, and pharmacokinetics of a regimen of atazanavir powder boosted with ritonavir and an optimized dual nucleoside reverse transcriptase inhibitor in pediatric patients…
- Trial name
- PRINCE2 (NCT01335698)
- Testing
- Atazanavir Sulphate, Ritonavir
- Where
- 32 sites in United States, Argentina and 9 more
- Volunteers
- 160 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients
To determine the proportion of patients whose plasma HIV-1 RNA level falls below the level of detection (< 400 copies/ml) at week 16 and 24 of study therapy.
- Trial name
- NCT00002178
- Testing
- Ritonavir, Nelfinavir mesylate, Saquinavir
- Where
- 2 sites in United States
- Volunteers
- 375 people
- Sponsor
- Hoffmann-La Roche
Healthy Participants
Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]PF-07321332 in Healthy Male Participants.
This study is to characterize mass balance and further the understanding of human pharmacokinetics, metabolism, and excretion of radiolabeled [14C]PF-07321332 in healthy male participants following oral administration with…
- Trial name
- NCT05178654
- Testing
- [14C]PF-07321332
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy Subjects
Study to determine the effect of steady-state plasma concentration of Tipranavir/ritonavir (TPV/r) on platelet aggregation in healthy subjects and investigate the effect of TPV/r at steady state plasma concentrations on other…
- Trial name
- NCT02251795
- Testing
- Tipranavir, Ritonavir, Darunavir
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Infection, Human Immunodeficiency Virus, HIV Infections
A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)
This study is designed to demonstrate the non-inferior antiviral activity of DTG/ABC/3TC fixed dose combination (FDC) once daily (OD) compared to atazanavir plus ritonavir (ATV+RTV) and tenofovir disoproxil fumarate/emtricitabine…
- Trial name
- NCT01910402
- Testing
- Dolutegravir/abacavir/lamivudine FDC, Atazanavir, Ritonavir
- Where
- 90 sites in United States, Argentina and 11 more
- Volunteers
- 499 people
- Sponsor
- ViiV Healthcare
Covid19
Study of PBI-0451 in Healthy Subjects.
This is a phase 1, placebo-controlled, blinded, randomized, dose escalation study of PBI-0451 in healthy subjects. PBI-0451 is a new chemical entity and inhibitor of the main protease of coronaviruses, including the SARS-CoV-2…
- Trial name
- NCT05011812
- Testing
- PBI-0451 Dose 1, PBI-0451 Dose 2, PBI-0451 Dose 3
- Where
- New Zealand
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Pardes Biosciences, Inc.
Human Immunodeficiency Virus Type 1
A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients
The purpose of this study is to evaluate the antiviral activity as measured by the change in viral load from baseline in the 14 days following initiation of treatment with 4 different dose regimens of TMC310911 co-administered…
- Trial name
- NCT00838162
- Testing
- TMC310911 75 mg twice daily, TMC310911 150 mg twice daily, TMC310911 300 mg twice daily
- Where
- 3 sites in Germany
- Volunteers
- 33 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Healthy
Bioavailability of Tipranavir/Ritonavir Paediatric Solution Compared to Tipranavir/Ritonavir Capsules in Healthy Female and Male Subjects
Study to determine the relative bioavailability of 500/200 mg of tipranavir/ritonavir (TPV/r) oral solution compared to 500/200 mg of TPV/r capsules following oral administration and to investigate the relative bioavailability of…
- Trial name
- NCT02251158
- Testing
- Tipranavir oral solution, Tipranavir capsules, Ritonavir oral solution
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
HIV-1 Infection
Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
The primary objective of this study is to evaluate the efficacy of switching from a regimen of 2 nucleos(t)Ide reverse transcriptase inhibitors (NRTIs) and a third agent to a fixed dose combination (FDC) of…
- Trial name
- BRAAVE 2020 (NCT03631732)
- Testing
- B/F/TAF, NRTIs, Third Agent
- Where
- 82 sites in United States
- Volunteers
- 496 people
- Sponsor
- Gilead Sciences
Healthy
A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs
The study purpose is to evaluate the potential for a pharmacokinetic drug-drug interaction, safety and tolerability when Narlaprevir, Ritonavir (used as a metabolic inhibitor) and Tenofovir disoproxil fumarate (part 1) and…
- Trial name
- NCT03537404
- Testing
- Narlaprevir, Ritonavir, Tenofovir Disoproxil Fumarate
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- R-Pharm
HIV Infections
A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients
The purpose of this study is to examine how the immune systems of HIV-infected patients react to 2 anti-HIV drug combinations.
- Trial name
- NCT00002448
- Testing
- Ritonavir, Efavirenz, Saquinavir
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
COVID-19
A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.
The purpose of this study is to learn about the effects of the study medicine called Paxlovid [nirmatrelvir-ritonavir/PF-07321332], for the potential treatment of COVID-19.
- Trial name
- NCT07261085
- Testing
- nirmatrelvir-ritonavir, No treatment
- Where
- United States
- Volunteers
- 99,000 people
- Sponsor
- Pfizer
COVID-19 Pneumonia
Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19
This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of GST-HG171/Ritonavir in the treatment of mild to moderate COVID-19.
- Trial name
- NCT05656443
- Testing
- GST-HG171/Ritonavir
- Where
- China
- Volunteers
- 1,246 people
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.